Publications database

A journalists’ guide to upcoming events and products from the EU drugs agency in Lisbon, May 2016.

This report explores the recent resurgence in use of MDMA in Europe and increased availability of high-strength MDMA tablets, crystals and powders. It notes that the picture is not uniform across European...

April–June 2016​ In this issue: 2016 EU Drug Markets Report | Monitoring illicit drugs in wastewater | UNGASS 2016 | Strengthening early warning on new synthetic opioids | New EMCDDA products and...

The EU Drug Markets Report 2016 is the second comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis provided in this report spans numerous...

This report includes estimates of the total size of the retail drug market in the European Union (EU) in 2013 for cannabis, heroin, cocaine, amphetamines and ecstasy. October 2018 : An error...

The EMCDDA strategy and work programme for 2016–18 and the 2016 annual work programme is based on the EMCDDA’s vision to contribute to a more secure and a healthier Europe. A more...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...

In this issue: Lisbon Addictions 2015 — conference round-up | Sponsored sessions at Lisbon Addictions 2015 | EMCDDA 20 years of monitoring conference | EMCDDA signs Memorandum of Understanding with Georgia |...

This publication presents the data and findings of the risk assessment on 4,4’-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of...

This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part...